retatrutide study news today Phase III demonstrates 30% weight loss Retatrutide UK Guide: Key Facts

Device : Used for delivering a drug (e.g., syringe, injector pen, wearable devices)

Lytvyn Y, Godoy LC, Scholtes RA, van Raalte DH, Cherney DZ (2019) Mineralocorticoid antagonism and diabetic kidney disease

[PubMed] 26.Scheen AJ, Lefbvre PJ

GI symptoms in diabetes mellitus are associated with both poor glycemic control and diabetic complications

Effects of liraglutide on cardiovascular outcomes in patients with diabetes with or without heart failure

It is often referred to as the silent killer because it typically presents no noticeable symptoms, yet it increases the risk of heart disease, stroke, and other serious conditions